ACUTE MYELOID LEUKEMIA (AML) · White paper
Acute Myeloid Leukaemia (AML) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About acute myeloid leukaemia (aml) — and why its trials are hard
Acute myeloid leukaemia is an aggressive clonal expansion of myeloid blasts (>=20% in blood or marrow by WHO criteria) that displaces normal haematopoiesis, causing anaemia, infection, and bleeding. Median age at diagnosis is about 68, so many patients cannot tolerate intensive induction, and the disease is molecularly heterogeneous (FLT3, NPM1, IDH1/2, TP53, CEBPA), meaning a single trial population may contain many biologically distinct diseases. This heterogeneity underpowers broadly enrolled studies and demands biomarker stratification. Trials are further complicated by high relapse and treatment resistance, treatment-related mortality that confounds survival analysis, and the difficulty of choosing endpoints: complete remission (CR) depends on subjective blast counts, overall survival is confounded by post-trial salvage and transplant, and minimal residual disease (MRD) assays vary in sensitivity. Strict eligibility often excludes the elderly and comorbid patients who make up most real-world cases. Precision-medicine enrichment, adaptive designs, MRD-negativity endpoints, and early FDA engagement are key improvements.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| venetoclax + azacitidine (Venclexta) | 2018 | newly diagnosed AML, adults ineligible for intensive chemotherapy | VIALE-A (accelerated approval 2018; confirmed 2020) | overall survival and composite complete remission | median OS 14.7 vs 9.6 months, HR 0.66 (95% CI 0.52-0.85); CR 36.7% vs 17.9% |
| midostaurin (Rydapt) | 2017 | newly diagnosed FLT3-mutated AML with intensive chemo | RATIFY (CALGB 10603) | overall survival and event-free survival | OS HR 0.77 (95% CI 0.63-0.95), p=0.016; median EFS 8.2 vs 3.0 months |
| CPX-351 (cytarabine/daunorubicin liposome) (Vyxeos) | 2017 | newly diagnosed therapy-related AML or AML-MRC, ages 60-75 | Study 301 (Lancet et al.) | overall survival and CR rate | median OS 9.6 vs 5.9 months, HR 0.69 (95% CI 0.52-0.90), p=0.005; CR 38% vs 26% |
| gilteritinib (Xospata) | 2018 | relapsed/refractory FLT3-mutated AML | ADMIRAL | overall survival vs salvage chemotherapy | median OS 9.3 vs 5.6 months, HR 0.64 (95% CI 0.49-0.83), p<0.001 (unverified exact CI) |
| ivosidenib (Tibsovo) | 2018 | IDH1-mutated AML (relapsed/refractory; later newly diagnosed) | AG120-C-001 (and AGILE with azacitidine) | CR + CRh rate; later event-free/overall survival | CR+CRh ~30-42% in R/R IDH1-mutated AML (exact rate unverified) |
| azacitidine (Vidaza) | 2004 | myelodysplastic syndromes and later AML (hypomethylating backbone) | CALGB 9221 (MDS) | overall response rate; delay to AML transformation/death | response rate primary endpoint in MDS; 55% of observation arm crossed over to azacitidine |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in acute myeloid leukaemia (aml) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| vosaroxin — NCT01191801 (VALOR) | failed to meet the primary endpoint of improved overall survival vs cytarabine in relapsed/refractory AML | modest OS signal did not reach significance in the overall population; highlighted need for more potent or better-stratified agents |
| volasertib (PLK1 inhibitor) — NCT01721876 (POLO-AML-2) | no OS benefit for volasertib + low-dose cytarabine; safety concerns (infections, fatal events) | the early Phase 2 survival trend did not hold in Phase 3, and toxicity offset any efficacy, underscoring the efficacy-tolerability balance in older AML patients |
| sapacitabine — NCT01303796 (SEAMLESS) | alternating decitabine/sapacitabine did not significantly improve OS vs decitabine alone | active but insufficiently differentiated regimen; supported a shift toward rationally designed combinations |
Choosing the right endpoint
Primary endpoints that matter in acute myeloid leukaemia (aml) trials
- Overall survival (OS) — The most definitive endpoint, but confounded by post-trial salvage therapy, allogeneic transplant, and deaths unrelated to AML; requires long follow-up.
- Complete remission (CR / CR with count recovery) — Requires <5% marrow blasts and haematologic recovery; blast counting is observer-dependent and recovery timing varies between patients.
- Minimal residual disease (MRD) negativity — Sensitive early predictor of relapse and survival, but not all patients have a trackable molecular marker and assay sensitivity differs across labs.
- Event-free survival (EFS) — Captures failure to achieve CR, relapse, or death, but the definition of an 'event' and relapse-detection sensitivity vary, causing inconsistency.
- Treatment-related mortality — In an older, comorbid population, early deaths from induction toxicity can obscure efficacy and must be tracked as a safety endpoint.
How iNGENū runs acute myeloid leukaemia (aml) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Acute Myeloid Leukaemia (AML) clinical trials — FAQs
Why is patient stratification so important in AML trials?
How did venetoclax change frontline AML treatment?
Why do many AML drugs fail in Phase 3 after promising early data?
Ready to discuss your acute myeloid leukaemia (aml) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal